Canada markets closed

Edwards Lifesciences Corporation (4EW.TI)

TLO - TLO Delayed Price. Currency in EUR
Add to watchlist
85.90+2.00 (+2.38%)
At close: 04:37PM CEST
Full screen
Previous Close83.90
Open87.38
Bid85.74 x N/A
Ask86.03 x N/A
Day's Range79.87 - 87.38
52 Week Range57.94 - 88.14
Volume15
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR

    NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus size or sex. These data were presented during the late-breaking clinical

  • PR Newswire

    BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE: EW), today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.

  • Business Wire

    Edwards Lifesciences to Sell Critical Care to BD

    IRVINE, CA, June 03, 2024--Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.